Clinical trials: Diagnostic
Glioblastoma, Glioblastoma Multiforme
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
There will be 2 phases in this study. Patients will either be enrolled to the first phase or to the second phase, depending upon when they enroll into the study.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
- Trial name
- NCT00402116
- Testing
- enzastaurin, temozolomide, radiation therapy
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Injection Site, Injection Site Reaction
Sorrel 25R Injector - Sorrel Clinical Study Protocol
A prospective, open-label, single-center pilot study to evaluate the performance, safety and usability of the investigational SWI Device in healthy volunteers.
- Conditions
- Injection Site, Injection Site Reaction, Injection Site Irritation
- Trial name
- NCT05221333
- Testing
- Sorrel Wearable Injector
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eitan Medical
Anovulation, Oligo-ovulation
Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
This is an open-label, parallel-group, randomized, multicenter Phase III trial to compare the efficacy and safety of a single 250 microgram (mcg) subcutaneous dose of MSJ-0011 to a single 5,000 international units (IU)…
- Conditions
- Anovulation, Oligo-ovulation, Hypothalamic-pituitary Dysfunction, Polycystic Ovarian Syndrome
- Trial name
- NCT01653743
- Testing
- MSJ-0011, urinary hCG (u-hCG), Follitropin alpha
- Where
- 6 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Glioblastoma
Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
This is a randomised, open-label, multi-centre, Phase II study in patients with newly diagnosed glioblastoma. 62 patients with newly diagnosed glioblastoma are enrolled in the study in a 1:2 allocation (standard of care (SOC)…
- Trial name
- ALECSAT (NCT02799238)
- Testing
- ALECSAT, Radiotherapy, Temozolomide
- Where
- 4 sites in Sweden
- Volunteers
- 62 people
- Sponsor
- CytoVac A/S
Traumatic Brain Hemorrhage
SAFETY: Stabilization Points to Third Hospital Line Assessment oF the Impact of the usE of Infrascanner Model 2500 to Provide Decision Support for Diagnosis/Screening of Traumatic Brain InjurY in Ukraine
The Infrascanner model 2500 is a handheld, noninvasive device that is FDA-cleared to detect traumatic intracranial hematomas. FDA clearance K200203 was issued in 2020, K211617 added pediatric age group to the IFU in 2022, and…
- Trial name
- SAFETY (NCT07014748)
- Testing
- Handheld brain hematoma detector
- Where
- 4 sites in United States, Ukraine
- Volunteers
- 600 people
- Sponsor
- InfraScan, Inc.
Obesity
Signature Diagnostic of Non-alcoholic Steatohepatitis (NASH) by Infrared Light Spectroscopy
Evaluation of the diagnostic performance of an algorithm developed to detect metabolic profiles specific of non-alcoholic steatohepatitis NASH and based on the reading of a blood sample's infrared spectra
- Trial name
- SIGNALS (NCT03978247)
- Testing
- NASHMIR
- Where
- Belgium
- Volunteers
- 382 people
- Sponsor
- Diafir
Glaucoma, Ocular Hypertension
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
The purpose of the study is to examine how preservative free tafluprost ophthalmic solution (0.0015%) is distributed in blood circulation after ocular administration in children who have glaucoma or elevated intraocular pressure.
- Trial name
- NCT02102750
- Testing
- Preservative free tafluprost opthalmic solution
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 17 people
- Sponsor
- Santen Oy
Acute Compartment Syndrome
The Use of Near Infrared Spectroscopy in the Diagnosis of Acute Compartment Syndrome
This is a prospective observational study to determine the reliability and accuracy of Near Infrared Spectroscopy (NIRS) to detect oxygen flow in the extremities of injured and non-injured soldiers over time.
- Trial name
- NCT01171638
- Testing
- Near infrared spectroscopy (NIRS)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- J&M Shuler
Rheumatoid Arthritis
Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate
The purpose of this clinical trial is to assess the safety, efficacy, tolerability, immunogenicity and pharmacokinetics of 3 dose levels of ART621 in the treatment of rheumatoid arthritis.
- Trial name
- NCT00928317
- Testing
- ART621
- Where
- 46 sites in United States, Argentina and 6 more
- Volunteers
- 13 people
- Sponsor
- Arana Therapeutics Ltd
Melanoma, Non-melanoma Skin Cancer
DERM Health Economics Study
This study aims to provide an initial assessment of the potential impact DERM could have on the number of onward referrals for a face to face dermatologist review and/or biopsy from a teledermatology-based service, and to improve…
- Trial name
- NCT04123678
- Testing
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- Skin Analytics Limited
AVRT, AVNRT
A Real-world Study of Cardiac Ablation for PSVT Using ST Catheter
Paroxysmal supraventricular tachycardia known as PSVT includes atrioventricular reentrant tachycardia (AVRT) and atrioventricular nodal reentrant tachycardia (AVNRT). This study is multicenter, retrospective, cohort study.
- Trial name
- ST in PSVT-RWS (NCT04923815)
- Testing
- THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Medical (Shanghai) Ltd.
Coronary Artery Disease, Myocardial Ischemia
The ADAPT Study: Assessment of the DiAgnostic Performance of DeepVessel FFR in SuspecTed Coronary Artery Disease
DEEPVESSEL FFR is a medical device that is designed to extract three- dimensional coronary tree structures and generate computed tomography-derived fraction flow reserve (FFR) values from coronary CT angiogram images.
- Trial name
- ADAPT (NCT04828590)
- Testing
- No intervention
- Where
- 10 sites in United States, Austria and 3 more
- Volunteers
- 302 people
- Sponsor
- Keya Medical
Acute Myelogenous Leukemia
MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia
This is a phase 1, open-label, multicenter study investigating the use of MLN518 in combination with standard chemotherapy to patients with newly diagnosed AML.
- Trial name
- NCT00274248
- Testing
- MLN518
- Where
- United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Brain Metastases
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current…
- Trial name
- NCT04365374
- Testing
- Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy
- Where
- 37 sites in United States
- Volunteers
- 230 people
- Sponsor
- GT Medical Technologies, Inc.
Brain Cancer
An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated (the MGMT gene is not altered by a chemical change).
- Trial name
- CheckMate 498 (NCT02617589)
- Testing
- Nivolumab, Temozolomide, Radiotherapy
- Where
- 125 sites in United States, Australia and 17 more
- Volunteers
- 560 people
- Sponsor
- Bristol-Myers Squibb
Dry Eye Disease
Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease
SURF-200 is being studied in people experiencing an episodic flare-up of their dry eye disease. SURF-200 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop.
- Trial name
- NCT04734210
- Testing
- 0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate
- Where
- 28 sites in United States
- Volunteers
- 139 people
- Sponsor
- Surface Ophthalmics, Inc.
Anemia of Chronic Disease
An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease
The objective of this study is to measure the change in blood values after the administration of an amino acid based erythropoietin stimulating system.
- Trial name
- NCT01846689
- Testing
- ESS (medical food/drug)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Targeted Medical Pharma
Covid19
Assessment of Efficacy of KAN-JANG® in Mild COVID-19
The complexity of COVID-19 suggests a potential need for a range of therapies, including antiviral agents, immunostimulants, immunosuppressants, adaptogens, and anticoagulants.
- Trial name
- NCT04847518
- Testing
- Kan Jang capsules
- Where
- Georgia
- Volunteers
- 140 people
- Sponsor
- Swedish Herbal Institute AB
Glioblastoma, Oligodendroglioma
RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
This is a two-part Phase I add-on clinical trial in newly diagnosed glioblastoma or GBM. By "add-on" what is meant is that the experimental intravenous therapy, RRx-001, is combined or "added on" to standard of care.
- Conditions
- Glioblastoma, Oligodendroglioma, Anaplastic Oligodendroglioma
- Trial name
- G-FORCE-1 (NCT02871843)
- Testing
- RRx-001 dose escalation with TMZ + RT, Radiation, Fixed dose Temozolomide (75 mg/m2)
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- EpicentRx, Inc.
Prostate Cancer
Evaluation of the Sentinel™ PCC4 Assay for Diagnosis, Prognosis and Monitoring of Prostate Cancer in Puerto Rico
The miR Scientific Sentinel™ Prostate Cancer Classifier Platform (Sentinel™ PCC4 Assay) is a new molecular assay that interrogates 442 small non-coding RNAs extracted from urinary exosomes and provides urologists an early, very…
- Trial name
- NCT04661176
- Testing
- miR Sentinel™ PCC4 Assay
- Where
- 3 sites in Puerto Rico
- Volunteers
- 500 people
- Sponsor
- miR Scientific LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.